Litigation Details for Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Docket		Date Filed	2012-07-09
Court	District Court, D. Delaware	Date Terminated	2015-06-22
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	8,129,342
Link to Docket	External link to docket

Details for Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-07-09				External link to document

Litigation summary and analysis for: Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Last updated: June 14, 2026

Cubist Pharmaceuticals Inc. v. Hospira Inc. (1:12-cv-00859): Litigation Summary, Docket Timeline, and Patent/Exposure Analysis

Cubist Pharmaceuticals Inc. v. Hospira Inc., No. 1:12-cv-00859, is a Hatch-Waxman patent infringement dispute filed in the U.S. District Court for the District of Delaware involving Cubist’s pharmaceutical patents and Hospira’s generic-drug challenge strategy. The case’s legal posture and downstream generic-entry risk are governed by (i) the asserted patent claims and (ii) any stipulations, claim constructions, summary-judgment rulings, and settlement terms affecting FDA approval timelines and market entry dates.

This matter’s litigation-lane and leverage points are determined by the following factors: the Orange Book listing status of Cubist’s product at filing, the specific patents asserted (drug substance, formulation, method-of-use, and/or manufacturing), the outcome of validity and infringement challenges, and whether the parties entered into a settlement that designates a “trigger” date for generic launch.

What patents were asserted in Cubist v. Hospira 1:12-cv-00859 and what do they cover?

Answer: The litigation’s scope is defined by the particular Cubist patents asserted in the complaint and any later amended pleadings. Those patents typically fall into one or more of:

• drug substance or composition of matter (active ingredient coverage)
• formulation or dosage-form patents (including crystalline forms, solid-state properties, excipient systems, or stability-related features)
• method-of-use patents (labeling-directed use claims)
• manufacturing-process patents (process steps that map to ANDA manufacturing)

Why this matters for business risk: Patent type drives both (a) the ease of designing around and (b) whether invalidity or non-infringement arguments can neutralize the asserted claims without waiting for full merits outcomes.

Claim categories and likely technical pressure points

Because Hatch-Waxman suits often target not only composition and formulation but also product performance attributes, the central technical questions that usually arise include:

• Does Hospira’s proposed ANDA product practice the claimed formulation constraints (e.g., excipient set, particle/crystal form, dissolution/stability specs)?
• If the asserted claims are method-of-use, does Hospira’s ANDA label induce infringement (the “label” infringement theory)?
• If manufacturing-process patents are asserted, do Hospira’s process descriptions (from ANDA materials) read on the claimed steps?

What the asserted patent set determines about the “design-around” window

• Composition/formulation claims: design-around can be possible by changing solid-state form or formulation structure, but litigation often turns on expert testimony and claim constructions.
• Method-of-use claims: design-around can be label-based (carve-outs or changed indications), but settlement typically coordinates labeling and launch timing.
• Manufacturing-process claims: design-around depends on process feasibility and evidence alignment during discovery.

What is the docket timeline for Cubist v. Hospira 1:12-cv-00859?

Answer: A Hatch-Waxman litigation docket normally follows a predictable structure. In this case, key milestone dates are driven by: complaint service, responsive pleadings, early Markman activity (if claim construction is contested), dispositive motions (Rule 12/56), trial or bench decision scheduling, and any stay or lift tied to settlement.

Typical docket phases in this case type (business-relevant checkpoints):

• Filing and initial complaint: defines asserted patents and relief sought (injunction against FDA approval and/or launch).
• Answer and defenses: frames infringement and invalidity theories.
• Claim construction (Markman): narrows claim scope and drives infringement verdict leverage.
• Summary judgment: resolves clear-cut invalidity or non-infringement.
• Trial and merits judgment (if not settled): determines whether Hospira can launch under the ANDA post-approval.
• Settlement or consent judgments: if reached, usually governs launch timing and patent carve-outs.

When did exclusivity and generic-entry “trigger” dates matter in Cubist v. Hospira 1:12-cv-00859?

Answer: The case’s practical consequence is whether and when Hospira can market its generic product without violating the asserted patents. The timing hinges on:

• patent expiration for the last asserted patent
• any court-ordered prohibition or injunction duration
• any settlement agreement launch date (often tied to a specific date, a patent expiry, or a non-infringement finding)
• FDA approval timing under the ANDA and whether it is effectively blocked by the litigation posture

Exclusivity mechanics that change launch exposure

• If the asserted patents expire after the ANDA approval date, the FDA can approve but the manufacturer is still blocked from commercial launch until the court/settlement pathway permits.
• If the case resolves early via non-infringement or invalidity, commercial launch risk can compress to the remaining regulatory and logistical ramp.

How strong is the patent estate for Cubist’s product in 1:12-cv-00859?

Answer: Litigation leverage generally increases when Cubist holds a layered estate (multiple patents across composition, formulation, and use). In Hatch-Waxman contests, stacked patents reduce “single-patent” exit risk and extend injunction leverage.

Strength indicators investors and litigators track:

• number of asserted patents at filing and whether Cubist amended to add additional coverage
• whether the asserted claims are core (composition/formulation) versus peripheral (narrow manufacturing details)
• whether the patents have been litigated previously (and survived challenges)
• whether claim constructions in other cases narrow or broaden scope of the relevant claim terms

What is the Orange Book status of Cubist’s listed patents in the 1:12-cv-00859 controversy?

Answer: Orange Book status determines whether the asserted patents are tied to FDA listing and whether Hospira’s ANDA must address them under 21 U.S.C. § 355(j). The Orange Book also drives how Paragraph IV certifications map to infringement arguments.

Business implications of Orange Book dynamics:

• If key patents are not Orange Book-listed for the relevant drug/product/strength, the asserted universe is smaller and injunction leverage can weaken.
• If patents are listed and Paragraph IV certifications were made, the litigation is a classic “pre-market gate” that can delay launch absent settlement.

Was there a Paragraph IV challenge in Cubist v. Hospira 1:12-cv-00859 and what does it imply?

Answer: The caption and nature of the case indicate a Hatch-Waxman patent infringement framework consistent with Paragraph IV-style ANDA certifications. A Paragraph IV premise means the generic filer challenged one or more Orange Book patents as invalid, unenforceable, or not infringed.

Litigation implications:

• Validity arguments typically focus on anticipation/obviousness based on prior art.
• Infringement arguments turn on product comparison, formulation composition, and label-based induced infringement if method-of-use claims exist.
• Enforceability arguments can turn on inequitable conduct or prosecution history issues.

What generic entry risks exist for Hospira if Cubist’s asserted claims were upheld?

Answer: If the court upheld infringement and validity of one or more asserted claims, Hospira’s risk is a commercial launch prohibition for the covered time window. The risk can persist even if Hospira wins on some patents because remaining asserted patents can still block market entry.

Key risk outcomes:

• Full win for Cubist: injunction or effective market exclusion until expiry or settlement date.
• Partial win for Cubist: Hospira may launch only if it can carve around the remaining claims or if settlement defines permissible launch contours.
• Full win for Hospira: commercial launch typically proceeds after FDA approval and remaining regulatory/labeling conditions.

What settlement or consent judgment terms affect launch timing in 1:12-cv-00859?

Answer: In Hatch-Waxman cases, settlements commonly:

• set a fixed launch date
• provide a covenant not to sue tied to specific patents
• require label carve-outs, dosing restrictions, or changes in indicated uses
• specify whether an injunction is lifted and whether any post-launch damages exposure exists

Business-relevant settlement levers to watch:

• whether the settlement is “all-patent” or “some-patent” scoped
• whether it includes provisions that constrain later patent filings or other enforcement
• whether it addresses appeals if a verdict is pending

Which companies are challenging Cubist and how does Hospira’s profile change competitive dynamics?

Answer: In this matter specifically, the named defendant is Hospira. Competitive impact depends on whether Hospira is the only ANDA filer at the FDA stage or whether other competitors have “next-in-line” eligibility.

How competitor structure affects value:

• If multiple filers exist, settlements can change the order of market entry.
• If Hospira is a leading filer with high manufacturing capacity, the settlement effectively determines the near-term pricing and volume compression for Cubist.

How does Cubist’s product compare with Hospira’s proposed ANDA for infringement risk?

Answer: In Hatch-Waxman product-design disputes, infringement risk is determined by:

• active ingredient identity and bioequivalence pathway
• formulation composition and manufacturing steps that map to claim limitations
• in vitro and in vivo performance parameters tied to method-of-use or formulation claim terms
• labeling for method-of-use infringement theories

What FDA regulatory status intersects with the litigation posture in 1:12-cv-00859?

Answer: Litigation affects the practical ability to commercialize after FDA approval. FDA approval does not equate to launch permission if the court maintains an injunction or if the settlement conditions restrict marketing.

Regulatory touchpoints typically used to time commercialization:

• ANDA approval date
• patent litigation stay or lifting based on court outcomes
• labeling negotiation and section viii statement alignment
• readiness for commercial distribution post-permitted date

What patent litigation affects Cubist beyond 1:12-cv-00859?

Answer: Cubist’s patent estate for the relevant drug class often extends beyond one ANDA defendant. Business impact is driven by whether parallel cases target the same core patent set or different improvements (different strengths, formulations, or delivery forms).

How to map cross-case pressure

• If other cases invalidate formulation claims, 1:12-cv-00859 may become leverage-limited.
• If other cases uphold different method-of-use or manufacturing claims, the market exclusion can still persist.

Key Takeaways

1. Case structure: Cubist v. Hospira (1:12-cv-00859) fits a standard Hatch-Waxman patent infringement model in which the asserted Orange Book-listed patents define whether Hospira can launch a generic product.
2. Decision drivers: The business outcome turns on the asserted patent claims’ category (composition/formulation/use/process) and the court’s rulings on infringement, validity, and enforceability.
3. Launch timing: Commercial entry risk is determined by the last surviving asserted patent outcome and any settlement terms that fix a launch date or carve out specific claims.
4. Patent estate value: A layered Cobist patent portfolio typically increases leverage and reduces the probability of a fast, full design-around outcome for Hospira.

FAQs

1. Does a favorable FDA ANDA approval allow launch during ongoing patent litigation?
2. How do claim constructions in a Hatch-Waxman case shift infringement risk for formulation versus method-of-use claims?
3. What evidence typically decides infringement of a formulation patent in ANDA disputes?
4. How do settlement launch dates usually relate to patent expiry and court injunctions?
5. Can multiple asserted patents in one case extend launch even if some patents are found invalid or not infringed?

References

No sources are cited because the requested case-specific patent assertions, docket events, and outcomes are not provided in the prompt, and producing a litigation summary with exact holdings or dates without citations would not meet accuracy requirements.